Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Deferred Taxes: 2021-2024

Historic Deferred Taxes for Prime Medicine (PRME) over the last 2 years, with Jun 2024 value amounting to -$134,000.

  • Prime Medicine's Deferred Taxes fell 532.26% to -$134,000 in Q2 2024 from the same period last year, while for Jun 2024 it was -$77,000, marking a year-over-year increase of 52.17%. This contributed to the annual value of -$279,000 for FY2023, which is 71.06% up from last year.
  • Per Prime Medicine's latest filing, its Deferred Taxes stood at -$134,000 for Q2 2024, which was down 200.00% from $134,000 recorded in Q1 2024.
  • In the past 5 years, Prime Medicine's Deferred Taxes ranged from a high of $1.2 million in Q4 2021 and a low of -$532,000 during Q1 2022.
  • In the last 3 years, Prime Medicine's Deferred Taxes had a median value of -$134,000 in 2024 and averaged -$138,111.
  • Examining YoY changes over the last 5 years, Prime Medicine's Deferred Taxes showed a top increase of 166.34% in 2024 and a maximum decrease of 532.26% in 2024.
  • Quarterly analysis of 4 years shows Prime Medicine's Deferred Taxes stood at $1.2 million in 2021, then plummeted by 116.25% to -$202,000 in 2022, then slumped by 150.94% to -$108,000 in 2023, then plummeted by 532.26% to -$134,000 in 2024.
  • Its last three reported values are -$134,000 in Q2 2024, $134,000 for Q1 2024, and -$108,000 during Q3 2023.